Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) whose cancer has come back or stopped responding to at least 2 previous treatments, or who have had a stem cell transplant, and who have either already tried CAR-T cell therapy or are not suitable candidates for it.
• People whose tumor has tested positive for certain proteins called CD19 or CD20 on at least 1% of cells, confirmed through a biopsy.
• People aged between 18 and 80 years.
• People who are reasonably able to carry out daily activities, as measured by a standard health performance scale (Karnofsky score of 60% or above).
• People whose blood counts meet minimum levels — specifically, a neutrophil count of at least 500/mm³ and a platelet count of at least 50,000/mm³.
• People whose kidneys are functioning well enough, with an estimated kidney filtration rate of at least 30 ml/min (confirm with trial site for how this is calculated).
• People whose liver is functioning adequately, based on standard blood test results — with some flexibility allowed if the lymphoma has spread to the liver, at the treating doctor's discretion.
• People whose lungs are functioning at 50% or more of expected capacity on breathing tests.
• People whose heart is pumping at 40% or more efficiency, with no uncontrolled heart rhythm problems or significant heart disease symptoms.
• Women who could become pregnant must not currently be pregnant or breastfeeding, and must have a negative pregnancy test before entering the trial.
• Women who cannot become pregnant must meet at least one of the following: have gone through menopause (no periods for 12 or more consecutive months), have had a hysterectomy or surgical removal of the ovaries, or have ovarian failure confirmed by hormone testing after receiving pelvic radiation (confirm with trial site).
• Women of childbearing potential who are sexually active must agree to use a highly effective form of contraception throughout the treatment period and for at least 3 months after finishing treatment. Acceptable methods include hormonal contraception, an intrauterine device (IUD), tubal ligation, hysterectomy, a partner who has had a vasectomy, implantable or injectable contraceptives, or condoms used with spermicide. Complete abstinence throughout the trial is also acceptable. If pregnancy occurs or is suspected during the trial, the treating doctor must be informed immediately.
• Men participating in the trial must agree to use effective contraception before, during, and for at least 4 months after completing treatment, and must notify their doctor immediately if they father or suspect they have fathered a child during the trial.
• People who agree to sign a consent form for long-term follow-up as required by the institution.

Who may not be able to join:

• People whose lymphoma is currently in complete remission with no measurable disease.
• People who have had major surgery within 4 weeks before the first dose of the study treatment.
• People with another severe or uncontrolled medical condition that could increase the risks of taking part.
• People with any other currently active cancer, except for previously treated early-stage cervical cell changes or certain non-melanoma skin cancers.
• People who are still experiencing significant side effects (grade 3 or higher) from previous cancer treatments that have not improved to a lower level.
• People with active hepatitis B (as a carrier or with detectable virus levels) or active hepatitis C (with a detectable viral load).
• People with an active infection currently being treated with antibiotics given through a drip or injection.
• People living with HIV.
• People who have received any cancer treatment — whether standard or experimental — within the past 2 weeks.
• People whose lymphoma has spread to the brain or spinal fluid and is currently untreated.
• People whose life expectancy is estimated to be 6 months or less.
• People with an active and uncontrolled neurological condition.
• People currently taking steroid medications (except for low-dose replacement doses), or who have received certain immune-suppressing medications — specifically antithymocyte globulin or lymphocyte immune globulin within the past 14 days, or alemtuzumab within the past 28 days.
• People currently receiving any medication that suppresses the immune system.

Important: Always verify eligibility with the trial site directly before applying.